Herve Hoppenot Net Worth

The estimated Net Worth of Herve Hoppenot is at least $41.5 Milión dollars as of 23 February 2021. Mr. Hoppenot owns over 12,925 units of Incyte stock worth over $17,943,503 and over the last 11 years he sold INCY stock worth over $8,421,464. In addition, he makes $15,151,200 as Chairman of the Board, President a Chief Executive Officer at Incyte.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Hoppenot INCY stock SEC Form 4 insiders trading

Herve has made over 5 trades of the Incyte stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 12,925 units of INCY stock worth $1,000,007 on 23 February 2021.

The largest trade he's ever made was exercising 124,148 units of Incyte stock on 26 June 2016 worth over $8,013,753. On average, Herve trades about 6,941 units every 38 days since 2014. As of 23 February 2021 he still owns at least 284,231 units of Incyte stock.

You can see the complete history of Mr. Hoppenot stock trades at the bottom of the page.

Herve Hoppenot biography

Herve Hoppenot is Chairman of the Board, President, Chief Executive Officer of Incyte Corporation. Mr. Hoppenot joined Incyte as President and Chief Executive Officer and a Director in January 2014, and was appointed Chairman of the Board in May 2015. Mr. Hoppenot served as the President of Novartis Oncology, Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG, a pharmaceutical company, from January 2010 to January 2014. Prior to that, Mr. Hoppenot served in other executive positions at Novartis Pharmaceuticals Corporation, serving from September 2006 to January 2010 as Executive Vice President, Chief Commercial Officer of Novartis Oncology and Head of Global Product Strategy & Scientific Development of Novartis Pharmaceuticals Corporation and from 2003 to September 2006 as Senior Vice President, Head of Global Marketing of Novartis Oncology. Prior to joining Novartis, Mr. Hoppenot served in various increasingly senior roles at Aventis S.A. (formerly Rhône Poulenc S.A.), a pharmaceutical company, including as Vice President Oncology US of Aventis Pharmaceuticals, Inc. from 2000 to 2003 and Vice President US Oncology Operations of Rhone Poulenc Rorer Pharmaceuticals, Inc. from 1998 to 2000.

What is the salary of Herve Hoppenot?

As the Chairman of the Board, President a Chief Executive Officer of Incyte, the total compensation of Herve Hoppenot at Incyte is $15,151,200. There are no executives at Incyte getting paid more.

How old is Herve Hoppenot?

Herve Hoppenot is 60, he's been the Chairman of the Board, President a Chief Executive Officer of Incyte since 2015. There are 10 older and 15 younger executives at Incyte. The oldest executive at Incyte Corp. is Pamela M. Murphy, 70, who is the VP of Investor Relations & Corp. Communications.

What's Herve Hoppenot's mailing address?

Herve's mailing address filed with the SEC is 1801 AUGUSTINE CUT-OFF, , WILMINGTON, DE, 19803.

Insiders trading at Incyte

Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... a Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.

What does Incyte do?

incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.

Complete history of Mr. Hoppenot stock trades at Incyte

Incyte executives and stock owners

Incyte executives and other stock owners filed with the SEC include:

• Herve Hoppenot,
  Chairman of the Board, President, Chief Executive Officer
• Steven Stein,
  Executive Vice President, Chief Medical Officer
• Wenqing Yao,
  Executive Vice President, Head of Discovery Chemistry
• Barry Flannelly,
  Executive Vice President and General Manager - US
• Christiana Stamoulis,
  Chief Financial Officer, Executive Vice President
• Maria Pasquale,
  Executive Vice President, General Counsel
• Herve Hoppenot,
  Chairman, Pres & CEO
• Paula Swain,
  Executive Vice President - Human Resources
• Christiana Stamoulis,
  Exec. VP & CFO
• Dr. Steven H. Stein,
  Exec. VP & Chief Medical Officer
• Dr. Vijay K. Iyengar M.D.,
  Exec. VP of Global Strategy & Corp. Devel.
• Dr. Barry P. Flannelly M.B.A., MBA, Pharm.D.,
  Exec. VP & GM of North America
• Dr. Barry P. Flannelly M.B.A., Pharm.D., MBA,
  Exec. VP & GM of North America
• Julian Baker,
  Lead Independent Director
• Paul Clancy,
  Independent Director
• Wendy Dixon,
  Independent Director
• Jacqualyn Fouse,
  Independent Director
• Jean-Jacques Bienaime,
  Independent Director
• Paul Friedman,
  Independent Director
• Edmund Harrigan,
  Independent Director
• Michael Booth,
  Vice President - Investor Relations
• Katherine High,
  Independent Director
• Vijay Iyengar,
  Executive Vice President, Global Strategy and Corporate Development
• Dashyant Dhanak,
  Executive Vice President, Chief Scientific Officer
• Thomas Tray,
  VP of Fin., Chief Accounting Officer & Controller
• Pamela M. Murphy,
  VP of Investor Relations & Corp. Communications
• Maria E. Pasquale,
  Exec. VP & Gen. Counsel
• Christine Chiou,
  Head of Investor Relations
• Dr. Dashyant Dhanak Ph.D.,
  Exec. VP & Chief Scientific Officer
• Michael James Morrissey,
  Exec. VP & Head of Global Technical Operations
• Reid M Huber,
  EVP, Chief Scientific Officer
• Julian14159, L.P.667, L.P.B...,
  
• David W Gryska,
  Executive Vice President, CFO
• Paul Trower,
  Principal Accounting Officer
• Julianbaker Felixbaker Bros...,
  
• Eric H. Siegel,
  EVP, General Counsel
• Paul A Brooke,
  Director
• Matteo Trotta,
  EVP, GM, Dermatology US
• Bros. Advisors Lp14159, L.P...,
  
• Bros. Advisors Lp Baker Bro...,
  
• Bros. Capital (Gp), Llcbake...,
  
• Schutter Richard U De,
  Director
• Barry A Ariko,
  Director
• Foundation Inc Damial,
  10% owner
• Daniel R Tisch,
  10% owner
• Julian Baker,
  Director
• Biotech Capital Ii Gp Llcba...,
  
• James M Daly,
  Exec. VP & Chief Comm. Officer
• Brothers Life Sciences Capi...,
  
• Laurent Chardonnet,
  VP Finance and Treasurer
• John A Keller,
  Exec VP & Chief Bus Officer
• Jon S Saxe,
  Director
• Biotech Capital (Gp), Llcba...,
  
• / Tisch Capital (Gp), Llcba...,
  
• Brothers Life Sciences Capi...,
  
• John F Niblack,
  Director
• Biotech Capital (Gp), Llcba...,
  
• Fred B Craves,
  Director
• Biotech Capital Gp Llcbaker...,
  
• David C Hastings,
  Exec VP & CFO
• Patricia A Schreck,
  EVP and General Counsel
• / Tisch Capital (Gp), Llcba...,
  
• Richard S Levy,
  EVP, Chief Drug Dev&Medical Of
• Biotech Capital (Gp), Llcba...,
  
• Scott W Hurley,
  
• Capital (Gp), Llcbaker Feli...,
  
• Matthew Emmens,
  Director
• / Tisch Capital (Gp), Llcba...,
  
• Capital (Gp), Llcbaker Juli...,
  
• Steven M. Friedman,
  EVP, Biology & Preclinical Dev
• Bros. Capital (Gp), Llcbake...,
  
• Julianbaker Felixbaker Bros...,
  
• James S Tisch,
  10% owner
• Bros. Capital (Gp), Llcbake...,
  
• Brian W Metcalf,
  
• Andrew H Tisch,
  10% owner
• Michael James Morrissey,
  EVP, Head of Tech. Operations
• Thomas J Tisch,
  10% owner
• Roy A Whitfield,
  Director
• Capital (Gp), Llcbaker Juli...,
  
• Biotech Capital Ii Gp Llcba...,
  
• Brothers Life Sciences Capi...,
  
• Bonnie J Tisch,
  10% owner
• Bros. Advisors Lp667, L.P.B...,
  
• Jonathan Elliott Dickinson,
  EVP, General Manager, Europe
• Bros. Advisors Lp Baker Bro...,
  
• Thomas Tray,
  Principal Accounting Officer
• Otis W Brawley,
  Director
• Bros. Advisors Lp667, L.P.B...,
  
• Pablo J Cagnoni,
  President, R&D
• Susanne Schaffert,
  Director
• Sheila A. Denton,
  EVP & General Counsel